Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Diabetes risk higher in postmenopausal women with breast cancer

22 Jul 2019

The risk of diabetes mellitus (DM) is higher among postmenopausal women who develop primary breast cancer, reports a new study.

Accessing the Taiwan National Health Insurance Research Database, researchers identified 4,607 postmenopausal women (mean age, 58.6±9.1 years) with primary breast cancer and 23,035 matched noncancer controls (mean age, 58.6±9.1 years). Cox proportional hazards analysis was performed to assess the relationship between breast cancer and DM risk.

The incidence rates of DM at 1, 5, 10 and 15 years after cancer diagnosis were 92.6, 49.5, 41.9 and 39.9 events per 1,000 person-years, respectively. In the same time span since the index date, the corresponding rates in controls were lower, at 53.6, 27.2, 24.5 and 24.0 events per 1,000 person-years.

Models adjusted for age, income, urbanization, comorbidities and other medical conditions further showed that the risk of DM 1 year after index date was significantly higher in those with breast cancer (adjusted hazard ratio [HR], 1.70, 95 percent CI, 1.40–2.05).

The same was true when DM risk was assessed at 5 (adjusted HR, 1.34, 1.17–1.54), 10 (adjusted HR, 1.27, 1.13–1.44) and 15 (adjusted HR, 1.24, 1.11–1.40) years.

Stratifying according to hormone therapy showed that at 1 year, women who were receiving hormone therapy were more likely to develop DM than those who were not, though significance was not achieved (adjusted HR, 1.22, 0.86–1.74). This indicated that the effect of breast cancer on DM risk was independent of hormone therapy, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.